Re: randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.

[1]  R. Theriault,et al.  High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study , 2000, The Lancet.

[2]  Terry L. Smith,et al.  Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. , 2000, Journal of the National Cancer Institute.

[3]  G. Hortobagyi,et al.  Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. , 1999, Annals of surgery.

[4]  P. Pedrazzoli,et al.  Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment. , 1999, Anticancer Research.

[5]  Terry L. Smith,et al.  Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy , 1999, Cancer.

[6]  J. Peterse,et al.  Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement , 1998, The Lancet.

[7]  J. Pater,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Bonadonna,et al.  Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Luini,et al.  Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Hortobagyi,et al.  Factors predicting long‐term survival for metastatic breast cancer patients treated with high‐dose chemotherapy and bone marrow support , 1994, Cancer.